StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

QuarterlyAnnual
Latest, Q2 2026
52.5%
Period ended Jun 30, 2026
Change on a year earlier
-24.2 pts
76.7% in Q2 2025
History
8 quarters
Since Q2 2024
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUbrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202652.5%-24.2 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202622.9%-6.4 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025-3.0%-69.2 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202534.2%–Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202576.7%-5.6 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202529.3%–Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202466.2%–Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q2 2024Jun 30, 202482.3%–Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗

Cite this data

StockData. (2026). AbbVie Ubrelvy (ubrogepant) — International operational (constant-currency) growth YoY (%) (%), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ubrelvy_intl_op_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.